Drawing for TEC REGEN

USPTO serial 79435713

TEC REGEN

Reviewed by CopyMark Law Group

Reg. 8465660Status 700Registered
Filing date
Status date
Registration date
Sep 29, 2026
Examiner
MESSICK, TABITHA LEE
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with TEC REGEN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

James R Menker

James R Menker Holley & Menker, PA60 Ocean Boulevard, Suite 3Atlantic Beach, FL 32233United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical products for the treatment of immune deficiency by promoting thymic regeneration, medical and veterinary preparations for the treatment of immune deficiency by promoting thymic regeneration; hygiene preparations for medical use, namely, disinfectants; pharmaceutical substances and preparations, in particular nanobodies being antibodies for medical purposes; antibodies for medical purposes, namely, therapeutic antibody fragments for the treatment of autoimmune diseases; antibodies for medical purposes, namely, nanobodies used as medicinal preparations for the treatment of autoimmune and cancerous diseases; chemical and biochemical preparations for medical use, namely, for the treatment of immune deficiency by promoting thymic regeneration; antibodies for medical purposes, namely, nanobodies used as chemical preparations for medical use; thymus-regenerating biotechnological preparations for medical use; diagnostic preparations for medical use; antibodies for medical purposes, namely, nanobodies used as diagnostic preparations for medical use; thymus-regenerating medicines; medicines containing nanobodies for the treatment of immune deficiency by promoting thymic regeneration.ACTIVE—
010Surgical apparatus and instruments; medical, dental and veterinary apparatus and instruments, namely, infusion and injection devices for administering biological preparations; medical instruments for administering nanobody-based agents.ACTIVE—
042Scientific and technological services, namely, research and design services in the field of biotechnology, regenerative medicine and thymus regeneration; industrial analysis of pharmaceutical and biotechnological preparations, industrial research in the field of biotechnology and regenerative medicine, and industrial design services; design, development and programming of computer software; scientific research and medical research and development of biopharmaceutical preparations for thymus regeneration and immune system restoration; research and development in the field of nanobody technology; consultancy in the field of nanobody technology research and biotechnological research; development and technical maintenance of genetic banks of antibody fragments; database design and development; Software as a Service (SaaS) services featuring software for biomedical research data; computer Platform as a Service (PaaS) services featuring computer platforms for biomedical research data; web hosting of computer databases.ACTIVE—
044Medical services; personalized medical diagnostic services based on nanobody technologies; medical testing for the diagnosis and treatment of persons.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 29, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Sep 29, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 11, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 11, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 6, 2026GPNXNOTIFICATION PROCESSED BY IB—
Aug 5, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 22, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 22, 2026OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jul 11, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 8, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 8, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 8, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 12, 2026RFNTREFUSAL PROCESSED BY IB—
Jan 25, 2026RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jan 24, 2026RFRRREFUSAL PROCESSED BY MPU—
Dec 23, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 22, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 22, 2025DOCKASSIGNED TO EXAMINER—
Nov 2, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 2, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 30, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance